Physician profile
Sanjeev Maniar
NPI 1851352181
$17,378.42
in general payments reported to CMS, 2019-2025
62 companies · $3,109 in 2025
The $3,109 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $716 · 2021: $1,495 · 2022: $3,361 · 2023: $4,361 · 2024: $2,938 · 2025: $3,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,141 · Travel and Lodging: $1,155 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,141.41 |
| Travel and Lodging | $1,155.17 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,827.38 | 2019-2023 | Infinity |
| Novartis Pharmaceuticals Corporation | $1,264.00 | 2019-2025 | |
| Abbvie INC. | $1,216.53 | 2021-2025 | |
| Genzyme Corporation | $1,126.95 | 2019-2025 | |
| Emd Serono, INC. | $986.15 | 2019-2025 | Mavenclad |
| Biogen, INC. | $928.62 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Boston Scientific Corporation | $850.49 | 2022-2025 | General - Dbs |
| E.R. Squibb & Sons, L.L.C. | $817.46 | 2020-2025 | Zeposia |
| Genentech USA, INC. | $803.38 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $753.12 | 2019-2023 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $642.14 | 2019-2025 | Ultomiris, Soliris |
| Medtronic USA, INC. | $608.75 | 2019 | |
| Ucb, INC. | $594.73 | 2020-2024 | Zilbrysq, Rystiggo, Briviact |
| Amgen INC. | $417.18 | 2021-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $349.57 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Maniar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.